Back to news
New Proteomics blood test unlocks better oesophageal cancer detection
@Source: smh.com.au
Newly published results from ASX-listed diagnostics trailblazer Proteomics International Laboratories have unveiled stunning new clinical findings for its simple PromarkerEso oesophageal cancer blood test, opening the way for the innovative blood test to be commercially released.
The test’s accuracy was demonstrated in a 259-person study across three patient groups in Australia and the United States. The results were posted overnight in the peer-reviewed journal Proteomes, providing a major academic rubber stamp for the technology.
The new findings showed that the test could detect a whopping 91.4 out of 100 patients with the heartburn-related cancer and correctly identify 98.9 per cent of people without it, offering a powerful, non-invasive alternative to costly and uncomfortable endoscopies.
Based on the results, PromarkerEso outperforms many tests currently used for screening other types of cancers. For context, the widely used Prostate-Specific Antigen blood test used to diagnose prostate cancer has an Area Under Curve (AUC) measurement of just 0.68, while PromarkerEso hit an exceptional AUC of 0.98. An AUC greater than 0.7 is considered to offer acceptable discrimination, while above 0.9 is considered outstanding.
Related News
14 Feb, 2025
Lakeside Condo w/ Rental Potential
05 Apr, 2025
Kevin De Bruyne to Leave Manchester City . . .
22 May, 2025
Novak Djokovic Seeks Revenge Against Mat . . .
17 May, 2025
How rejecting a job offer led Mariners c . . .
11 Mar, 2025
“NPP shall be back 2028, we shall be bac . . .
09 Jul, 2025
Michael Phelps expresses astonishment at . . .
05 Jun, 2025
Gen AI Rewriting The Rules Of Retail
07 Apr, 2025
Muser to represent PNG in development pr . . .